BAROSTIM NEO™ is the World’s First Heart Failure Neuromodulation Device MINNEAPOLIS, June 30, 2020 /PRNewswire/ — CVRx, Inc., a private medical device company, announced today that its BeAT-HF phase III randomized clinical trial results were published in the Journal of the American College of Cardiology (“JACC”). Results from the trial were used […]
Tag: CVRx
BAROSTIM™ NEO Associated with Very High Responder Rates in Women
BeAT-HF Trial Results Presented as Late-Breaking Clinical Science at ESC Heart Failure 2020 Meeting MINNEAPOLIS, June 23, 2020 /PRNewswire/ — CVRx, Inc., a private medical device company, announced new BeAT-HF trial results from late-breaking clinical science presented virtually at the European Society of Cardiology Heart Failure 2020 Scientific Sessions. The BAROSTIM NEO […]



